Valbiotis SA (ALVAL) AI Stock Analysis

• Market Cap: €21.44M
• Dividend Yield: N/A
• Average Volume (3M): 150.46K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: FR
• Employees: 44
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.41
• Shares Outstanding: 23,698,235
• 10 Day Avg. Volume: 99,784
• 30 Day Avg. Volume: 150,457
• PEG Ratio: -0.31
• Price to Book (P/B): 1.27
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.69
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €1.00
• Price Target Upside: 11.11% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: €1.00 ▲(11.11%Upside)

The overall stock score of 45 reflects significant financial performance challenges due to consistent profitability and cash flow issues. Technical analysis further indicates bearish market sentiment with the stock trading below key moving averages. Valuation concerns are emphasized by the negative P/E ratio and lack of dividend yield, highlighting the risks associated with the stock.

Valbiotis SA Business Overview & Revenue Model

Company Description

Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.

How the Company Makes Money

Valbiotis SA generates revenue through the development and commercialization of its proprietary plant-based health solutions. The company engages in partnerships with major global healthcare companies to co-develop and market its products, often receiving milestone payments and royalties on product sales. Additionally, Valbiotis benefits from grants and funding for its research projects, contributing to its financial resources. Key revenue streams include licensing agreements, collaborations with pharmaceutical companies, and sales of its flagship products once they achieve regulatory approval.

Valbiotis SA Financial Statement Overview

Summary

Valbiotis SA faces significant profitability and cash flow hurdles, with negative margins and cash flow deficits indicating operational inefficiencies. The balance sheet is relatively stable, but declining equity levels and increasing net debt pose risks to financial stability.

Income Statement

Valbiotis SA has shown inconsistent revenue growth with a significant decline in 2024. The company has maintained negative margins across all years, indicating a struggle to achieve profitability. The gross profit margin is negative for 2024, and net profit margins remain deeply negative. These factors point to persistent operational challenges.

Balance Sheet

The balance sheet reveals a manageable debt-to-equity ratio and a relatively stable equity ratio, with stockholders' equity maintaining a healthy proportion of total assets. However, declining equity levels over the years and increasing net debt are concerns that could impact financial stability.

Cash Flow

Valbiotis SA's cash flow statement highlights negative free cash flow, with operating cash flow consistently negative, indicating reliance on external financing. The free cash flow has worsened in 2024 compared to previous years, and a declining free cash flow to net income ratio emphasizes cash flow challenges.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	175.00K	4.73M	785.00K	298.00K	3.09M
Gross Profit	-2.44M	2.69M	767.00K	282.00K	3.09M
EBITDA	-9.17M	-6.41M	-11.13M	-7.46M	-2.37M
Net Income	-10.03M	-7.37M	-12.31M	-8.68M	-3.83M
Balance Sheet
Total Assets	19.61M	33.31M	27.17M	28.48M	21.00M
Cash, Cash Equivalents and Short-Term Investments	11.58M	25.02M	20.83M	21.82M	14.59M
Total Debt	5.72M	6.88M	7.18M	7.59M	7.01M
Total Liabilities	9.24M	13.71M	13.86M	14.25M	13.93M
Stockholders Equity	10.37M	19.60M	13.31M	14.23M	7.07M
Cash Flow
Free Cash Flow	-11.80M	-8.30M	-9.48M	-7.58M	2.36M
Operating Cash Flow	-11.54M	-8.06M	-9.19M	-7.16M	2.69M
Investing Cash Flow	-61.00K	-250.00K	-197.00K	-7.00K	-332.00K
Financing Cash Flow	-1.84M	12.49M	8.40M	14.40M	4.19M

Valbiotis SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.90
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALVAL, the sentiment is Negative. The current price of 0.9 is above the 20-day moving average (MA) of 0.83, below the 50-day MA of 0.95, and below the 200-day MA of 1.17, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 49.87 is Neutral, neither overbought nor oversold. The STOCH value of 67.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALVAL.

Valbiotis SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.36B	-0.07	-63.77%	2.81%	16.35%	0.03%
ALVAL	45 Neutral	€21.44M	―		―	―	―
0RCQ	―	€21.07M	―		―	―	―
G49N	―	€19.22M	―		―	―	―
3MM	―	€18.87M	―		―	―	―
82F	―	€14.89M	―	-313.76%	―	―	―
ALPAT	―	€10.62M	11.32		―	―	―

Valbiotis SA Corporate Events

Valbiotis Announces Monthly Voting Rights and Share Capital Update

Valbiotis has announced its monthly information on the total number of voting rights and shares making up its share capital as of February 28, 2025. The company emphasizes the importance of compliance with its statutes regarding threshold crossings, which require shareholders to notify the company if their holdings reach certain percentages of the company’s capital. This announcement highlights Valbiotis’ commitment to transparency and regulatory compliance, which is crucial for maintaining investor confidence and ensuring proper governance.